Daniela Cesana

Daniela Cesana

Auto-generated profile, based on publicly available information

Daniela Cesana

San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2006 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
EMEugenio Montini
Eugenio Montini
DCDaniela Cesana
Daniela Cesana
MSManfred Schmidt
Manfred Schmidt
FSFrancesca Sanvito
Francesca Sanvito
MPMaurilio Ponzoni
Maurilio Ponzoni
LNLuigi Naldini
Luigi Naldini

1 April 2009 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
EMEugenio Montini
Eugenio Montini
DCDaniela Cesana
Daniela Cesana
MSManfred Schmidt
Manfred Schmidt
FSFrancesca Sanvito
Francesca Sanvito
CBCynthia C. Bartholomae
Cynthia C. Bartholomae
LNLuigi Naldini
Luigi Naldini
γ-Retroviral vectors (γRVs), which are commonly used in gene therapy, can trigger oncogenesis by insertional mutagenesis. Here, we have dissected the contribution of vector design and viral integration site selection (ISS) to oncogenesis using an in vivo genotoxicity assay based on transplantation of vector-transduced tumor-prone mouse hematopoietic stem/progenitor cells. By swapping genetic elements between γRV and lentiviral vectors (LVs), we have demonstrated that transcriptionally active long terminal repeats (LTRs) are major determinants of genotoxicity even when reconstituted in LVs and that self-inactivating (SIN) LTRs enhance the safety of γRVs. By comparing the genotoxicity of vectors with matched active LTRs, we were able to determine that substantially greater LV integration loads are required to approach the same oncogenic risk as γRVs. This difference in facilitating oncogenesis is likely to be explained by the observed preferential targeting of cancer genes by γRVs. This integration-site bias was intrinsic to γRVs, as it was also observed for SIN γRVs that lacked genotoxicity in our model. Our findings strongly support the use of SIN viral vector platforms and show that ISS can substantially modulate genotoxicity.

21 August 2011 in Nature Methods
Verified
Journal Article
Closed access
PDF file
ALAngelo Lombardo
Angelo Lombardo
DCDaniela Cesana
Daniela Cesana
PGPietro Genovese
Pietro Genovese
BSBruno Di Stefano
Bruno Di Stefano
EPElena Provasi
Elena Provasi
LNLuigi Naldini
Luigi Naldini

19 May 2011 in Blood
Verified
Journal Article
Open access
PDF file
ABAlessandra Biffi
Alessandra Biffi
CBCynthia C. Bartolomae
Cynthia C. Bartolomae
DCDaniela Cesana
Daniela Cesana
NCNatalie Cartier
Natalie Cartier
PAPatrik Aubourg
Patrik Aubourg
EMEugenio Montini
Eugenio Montini
A recent clinical trial for adrenoleukodystrophy (ALD) showed the efficacy and safety of lentiviral vector (LV) gene transfer in hematopoietic stem progenitor cells. However, several common insertion sites (CIS) were found in patients' cells, suggesting that LV integrations conferred a selective advantage. We performed high-throughput LV integration site analysis on human hematopoietic stem progenitor cells engrafted in immunodeficient mice and found the same CISs reported in patients with ALD. Strikingly, most CISs in our experimental model and in patients with ALD cluster in megabase-wide chromosomal regions of high LV integration density. Conversely, cancer-triggering integrations at CISs found in tumor cells from γretroviral vector–based clinical trials and oncogene-tagging screenings in mice always target a single gene and are contained in narrow genomic intervals. These findings imply that LV CISs are produced by an integration bias toward specific genomic regions rather than by oncogenic selection.

1 April 2014 in Molecular Therapy
Verified
Journal Article
Open access
DCDaniela Cesana
Daniela Cesana
MRMarco Ranzani
Marco Ranzani
MVMonica Volpin
Monica Volpin
CBCynthia Bartholomae
Cynthia Bartholomae
CDCaroline Duros
Caroline Duros
EMEugenio Montini
Eugenio Montini
Self-inactivating (SIN) lentiviral vectors (LV) have an excellent therapeutic potential as demonstrated in preclinical studies and clinical trials. However, weaker mechanisms of insertional mutagenesis could still pose a significant risk in clinical applications. Taking advantage of novel in vivo genotoxicity assays, we tested a battery of LV constructs, including some with clinically relevant designs, and found that oncogene activation by promoter insertion is the most powerful mechanism of early vector-induced oncogenesis. SIN LVs disabled in their capacity to activate oncogenes by promoter insertion were less genotoxic and induced tumors by enhancer-mediated activation of oncogenes with efficiency that was proportional to the strength of the promoter used. On the other hand, when enhancer activity was reduced by using moderate promoters, oncogenesis by inactivation of tumor suppressor gene was revealed. This mechanism becomes predominant when the enhancer activity of the internal promoter is shielded by the presence of a synthetic chromatin insulator cassette. Our data provide both mechanistic insights and quantitative readouts of vector-mediated genotoxicity, allowing a relative ranking of different vectors according to these features, and inform current and future choices of vector design with increasing biosafety.

22 November 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RGRichard Gabriel
Richard Gabriel
RERalph Eckenberg
Ralph Eckenberg
APAnna Paruzynski
Anna Paruzynski
CBCynthia C Bartholomae
Cynthia C Bartholomae
ANAli Nowrouzi
Ali Nowrouzi
MSManfred Schmidt
Manfred Schmidt